Skip to main content

Table 3 Incidence of Grade 3/4 adverse events

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

 

FN

Neutropenia

Nausea/Vomiting

Fatigue

Diarrhoea

Alopecia

Pemetrexed

2.59%

4.66%

1.55%

5.70%

0.52%

7.25%

Docetaxel

15.79%

41.58%

1.58%

5.79%

1.58%

38.95%

  1. Source: Eli Lilly, data on file, JMEI trial, 2008
  2. FN: febrile neutropenia
  3. Adverse events for the most common Grade 3/4 rates from the predominantly non-squamous population from the JMEI trial, 2008.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us